The U.S. FDA has approved an expanded indication for the Resolute drug-eluting stent (DES) platform – including the Resolute Onyx and Resolute Integrity DES – from Dublin-based Medtronic plc to treat patients with coronary artery disease who have de novo chronic total occlusion (CTO) Read More
